Samsung Biologics' Accounting Violation's Impact on Samsung C&T and Rest of the Korean Pharmas
On May 1st, 2018, Korea's Financial Supervisory Service (FSS) announced that Samsung Biologics Co., Ltd (207940 KS) violated accounting rules after...
173 Views
All Roads Lead to Samsung C&T
The margin of safety in Samsung C&T Corp (028260 KS) has become a lot more attractive versus one or two years ago. In this report, we...
233 Views
A Conversation with Biogen
Biogen Inc (BIIB US) is Samsung Biologics Co., Ltd (207940 KS) 's minority (5.4%) partner in the Samsung Bioepis JV that manufactures and sells...
334 Views
Binex - Paving the Way for Next-Gen Biotech Breakthrough
We met with Mr. HJ Lee, CEO & President of Binex, followed by a quick site tour in Incheon, Korea, and learned that the company has recently...
329 Views
Wuxi Biologics Placement - In Time for the Next Lock-Up, Returns Will Probably Not Match Prior Ones
WuXi Biologics (Cayman) Inc. (2269 HK) plans to raise around US$600m through a mix of primary (85%) and secondary (15%) offering. This will be the...
301 Views